Analysts anticipate Roivant Sciences to report an earnings per share (EPS) of $-0.16. The announcement from Roivant Sciences is eagerly anticipated, with investors seeking news of surpassing estimates ...

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Roivant Sciences Ltd. (NASDAQ:ROIV) while keeping the price ...

The presentation and webcast details will also be available under “Even Roivant Sciences is making serious changes to subsidiary Immunovant, announcing Monday a series of C-suite changes and new ...

Roivant Sciences Ltd. has seen a slight gain of 10% in its stock over the past 10 months, since my "buy" recommendation last May. The company has a differentiated drug development pipeline ...

Roivant Sciences exhibits a strong financial outlook, backed by its substantial cash position, strategic acquisitions, and efficient R&D expense management. The company's innovative drug pipeline ...

Roivant Sciences BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its founder Vivek Ramaswamy has ...

Roivant Sciences' shares are up more than 42% over the past year. The company recently released a report on a phase 3 trial of its atopic dermatitis treatment. The company's other main therapy ...

Baker Bros. Advisors has been steadily buying Acadia Pharmaceuticals and Roivant Sciences this year. Both companies could be significantly undervalued right now. A top hedge fund has been steadily ...

Roivant Sciences (NASDAQ:ROIV) has observed the following analyst ratings within the last quarter: These 7 analysts have an average price target of $16.57 versus the current price of Roivant ...

Roche ROG0.27%increase; green up pointing triangle Holding has agreed to buy the developer of a bowel-disease treatment from Roivant Sciences ROIV-0.64%decrease; red down pointing triangle ...

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib ...